Kornimate/medical-research-clean huggingface dataset:
anastrozole and fulvestrant compared to anastrozole as adjuvant treatment of postmenopausal patients with breast cancer

Conditions: Breast Cancer

Summary: purpose is to compare the frequency of events (presence of disseminated tumour cells, clinical recurrence and/or death) after 1 and 2 years of adjuvant treatment with anastrozole and fulvestrant or anastrozole alone in patients with early breast cancer.


Eligibility criteria:
inclusion criteria: * postmenopausal women with hormone receptor-positive early breast cancer and a positive disseminated tumour cell immunocytochemical result from bone marrow aspiration prior to randomisation exclusion criteria: * inflammatory and/or metastatic breast cancer. * current or previous malignancy within previous 5 years (other than breast cancer or adequately treated non-melanoma skin cancer or in-situ cervical cancer). * history of bleeding diathesis.

Keywords: breast neoplasms breast cancer early breast cancer oncology cancer breast cancer micrometastasis fulvestrant
comparing the effects of two beta blockers,metoprolol and nebivolol,on ambulatory blood pressure and basal metabolic rate

Conditions: Hypertension

Summary: the purpose of the study is to compare the effects of nebivolol and metoprolol on 24-hour ambulatory blood pressure characteristics and basal metabolic rates in patients with hypertension.


Eligibility criteria:
inclusion criteria: * 18 years old or older * currently be treated at a university of ms medical center internal medicine clinics * currently taking metoprolol succinate for hypertension * have their hypertension controlled (\<140/90). exclusion criteria: * uncontrolled hypertension * severe renal or moderate hepatic impairment * currently taking cyp 2d6 inducers/inhibitors * recent stroke (less than 6 months) * recent myocardial infarction (less than 6 months) * congestive heart failure * diagnosed obstructive sleep apnea * atrial fibrillation * arm circumference \>50 cm

Keywords: hypertension beta-blockers ambulatory blood pressure basal metabolic rate quality of life
vaccination against human papillomavirus (hpv) after allogeneic stem cell transplantation

Conditions: Recipients of Allogeneic Stem Cell Transplantation; HPV (Human Papillomavirus)-Associated; Acute Myeloid Leukaemia; Myelodysplastic Syndrome; Diffuse Large B Cell Lymphoma (DLBCL)

Summary: patients who undergo allogeneic stem cell transplantation lose previously acquired immunity and are routinely revaccinated against many infectious diseases. for several reasons, these patients have a long-term immune deficiency due to the transplant itself (lack of immune reconstitution) and due to possible complications, primarily gvhd and its treatment. the risk of secondary malignancy in the long-term following an allogeneic bone marrow transplant is greatly increased, and secondary cancer cases account for a significant proportion of late deaths in both women and men after transplantation. some of these secondary cancers are associated with hpv. the risk of cervical cancer has been reported to be 13 times increased compared to a healthy population. therefore in this trial, the aim is to study immune response (antigen-specific antibody response) after vaccination with 9-valent hpv vaccine (gardasil 9®) in adult women and men (up to and including 45 years of age) who have undergone allogeneic stem cell transplantation. in this trial, the sponsor will compare "early" (start 9 months after tx) with "late" (start 15 months after tx) vaccination.


Eligibility criteria:
inclusion criteria: * recipient of allosct from related or unrelated donor. * adults (men and women) ≥18 years up to and including 45 years of age for vaccination. * patients can be included regardless of prior hpv vaccination prior to transplantation exclusion criteria: * severe thrombocytopenia (under 50 x 10\^9) not allowing intramuscular injection * severe acute gvhd grade iii-iv. * extensive chronic gvhd requiring treatment with prednisone doses above 0.7 mg/kg/day plus at least two other systemic treatments against gvhd (for example ruxolitinib or photopheresis). * prednisone doses above 1mg/kg/day at study start. * treatment with rituximab 6 months before start of vaccination. doses given later (unusual) do not require exclusion. * treatment within 3 months before start of vaccination with iv or sc immunoglobulin. * pregnancy, pregnancy desire or active pregnancy planning during time vaccine is given and up to three months after last vaccine dose. * treatment with blood thinning medication contraindicating intramuscular injection * allergy against gardasil 9
health benefits of repeated treatment in pediatric schistosomiasis

Conditions: Schistosomiasis

Summary: objective and hypotheses: this project has the overall objective of implementing and evaluating new approaches to reducing the current and future burden of urinary schistosomiasis in young children using the antihelminthic drug praziquantel. the investigators hypotheses are that (1) praziquantel treatment will be as effective in children 1 to 5 years of age (who are routinely excluded from schistosomiasis control programmes) as it is in older 6-10 year old children and (2) two treatments will be more effective than a single treatment, especially in children 1 to 5 years of age.

this study aims to address the present health inequity by refinement of an existing drug regimen to improve the current and future health of pre-school children and infants. praziquantel is cheap, highly efficacious and safe, presenting a realistic opportunity of using a pre-existing tool in a modified way to benefit child health and development. the study will focus on children aged 1 to 10 years of age, comparing the impact of single vs. double treatment with pzq on the current and future health status of the children. the immediate health benefits of pzq treatment in children aged 6-10 years of age have already been documented and therefore by including 6-10 year olds in the proposed study, we can determine if the effects of pzq treatment on health and morbidity measures is age dependent. by killing worms pzq stops the morbidity related to the presence of worms and eggs such as anaemia, abdominal pain, diarrhoea and blood in the urine. therefore the study will investigate the immediate health benefits of treating pre-school children and infants.

Eligibility criteria:
inclusion criteria: 1. lifelong residents of the area 2. have provided at least 2 urine and 2 stool for parasitological examination 3. have given a blood sample before and after each treatment episode 4. be negative for hookworm, trichuris and ascaris exclusion criteria: 1. clinical signs of tuberculosis or malaria 2. presenting with fever 3. have had a recent major operation, illness or vaccination 4. have previously received antihelminthic treatment

Keywords: paediatric schistosomiasis morbidity immunology
effectivity of dermatix in promoting scar maturation

Conditions: Hypertrophic Scars

Summary: the purpose of this research is to demonstrate effectivity of dermatix in promoting maturation of the scar, versus a control region that will be treated with an indifferent cream.

the healing of deep thermal injuries is always associated with scarring. the healing process can lead to the formation of large scar bundles (e.g. hypertrophic scars). the scars can be discomforting, disfiguring and restrict motion if situated over or near joints. evidence for effectivity of treatment for reduction of hypertrophic scars or the prevention of them is limited. different treatments are used such as intralesional injected steroids, topically used oily creams, silicone sheets or occlusive dressings. compression garments are also frequently used. there is some evidence as to the effectivity of silicone sheets for recuction of hypertrophic scarring, however, these sheets cannot be used easily on all anatomical locations. valeant pharmaceuticals international has developed a silicone based scar remodelling gel, dermatix®, which has been empirically shown by others to have potential to reduce hypertrophic scars. primary objectives are to demonstrate effectivity of dermatix in promoting maturation of the scar, versus a control region that will be treated with an indifferent cream.

Eligibility criteria:
inclusion criteria: 1. patients with hypertrophic scarring and/or ropes, stable for at least 3 months before inclusion. 2. written informed consent 3. scar size enabling the definition of two distinct scar areas, with similar scar characteristics at inclusion, preferably symmetric scars. 4. patients of 18 years or older exclusion criteria: 1. known sensitivity for occlusive dressings or silicone containing products 2. any patient condition that may influence the compliance of the treatment negatively.

Keywords: hypertrophy scarring scar treatment silicone
a pilot study using 18f-dopa pet-guided radiotherapy in gliomas

Conditions: Malignant Glioma

Summary: for most brain tumors, radiation treatment is guided by a magnetic resonance imaging (mri) scan. in this study, information from a special scan, called a positron emission tomography/ computed tomography (pet/ct) scan using an amino acid called fluorine-18-l-dihydroxyphenylalanine (18f-dopa) will also be used. this type of scan has shown promise in being able to better distinguish tumor from normal brain tissue and may help to more accurately plan radiation treatment. this type of scan can also assist the radiation oncologist in identifying the most aggressive regions of the tumor. the goal of this study is to compare the 18f-dopa pet/ct scan with the mri scan for identifying where the disease is that needs to be treated with radiation.


Eligibility criteria:
inclusion criteria: * age ≥7 years. * biopsy confirmed newly diagnosed or recurrent who grade ii or grade iii malignant glioma. * ct simulation, 18f-dopa pet imaging, and standard of care pre-radiotherapy mri scans to be performed at mayo clinic rochester. * willing to sign release of information for any follow-up records. * provide informed written consent. exclusion criteria: * patients diagnosed with who grade iv malignant glioma. * patients previously treated with radiation therapy. * unable to undergo mri scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure). * unable to undergo an 18f-dopa pet scan (e.g. parkinson's disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists) * pregnant women * nursing women * men or women of childbearing potential who are unwilling to employ adequate contraception

Keywords: malignant glioma fdopa pet ct radiation therapy
digital sizing for orthopaedic hip implants

Conditions: Hip Arthritis

Summary: hip implants come in different sizes. currently, surgeons predict the implant size that will be needed using an analogue method whereby photos of the implant sizes are overlaid on the x-rays. in this study, we propose to use a digital, computerized method of templating which we expect will be more accurate than the overlay method.


Eligibility criteria:
inclusion criteria: * patients booked for primary total hip arthroplasty with non-cemented prosthesis. * no previous surgery/fractures to acetabulum or femur or hip. * no gross bony abnormality except for osteoarthritis and avascular necrosis. exclusion criteria: * cancer or tumor suspected, morbid obesity, revision, previous acetabular/femur/hip surgery, gross bony deformity, calibration bar not completely pictured on radiograph, unsuccessful surgery fracture/cancer/cemented prosthesis used.

Keywords: hip arthritis implant sizing
identification of de novo fanconi anemia in younger patients with newly diagnosed acute myeloid leukemia

Conditions: Childhood Acute Erythroleukemia (M6); Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloblastic Leukemia With Maturation (M2); Childhood Acute Myeloblastic Leukemia Without Maturation (M1); Childhood Acute Myelomonocytic Leukemia (M4); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Fanconi Anemia; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Secondary Myelodysplastic Syndromes; Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies

Summary: this research study is studying identification of de novo fanconi anemia in younger patients with newly diagnosed acute myeloid leukemia. studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to fanconi anemia in patients with acute myeloid leukemia.

primary objectives: i. identify children with newly diagnosed acute myeloid leukemia (aml) treated on cog-2961 and cog-aaml03p1 who are at high risk of having de novo fanconi anemia. ii. procure diagnostic samples from the cog aml biology repository and identify fanconi anemia patients using western blot techniques. outline: previously collected cryopreserved cells are analyzed via western blot to identify patients with fanconi anemia.

Eligibility criteria:
inclusion criteria: * treated on cog-2961 or cog-aaml03p1 * at high risk of having fanconi anemia, defined as meeting one the following groups of clinical criteria: * group 1: prolonged neutropenia after induction, severe regimen-related toxicity (mucositis, veno-occlusive disease, end-organ damage) * group 2: early non-relapse death (induction, consolidation) * group 3: small-for-weight, secondary malignancies
ptc in personalizing neoadjuvant therapy for patients with advanced gastrointestinal tumor

Conditions: Gastrointestinal Neoplasms

Summary: to explore the value of ptc drug screening technique in selecting neoadjuvant therapy for advanced gastrointestinal cancer.

in this study, patients diagnosed with advanced gastrointestinal cancer including locally advanced gastric cancer, locally advanced colorectal cancer and colorectal cancer with liver metastasis. tumor sample will be collected by endoscopy biopsy, needle biopsy or surgery, which will used for ptc drug screening. patients will be randomized to two groups. patients in experiment group will receive neoadjuvant therapy based on ptc drug screening, and patients in control group will receive neoadjuvant therapy based on clinical experience. 2-4 cycles of neoadjuvant therapy will be administered. patients appropriate for surgery will receive radical surgery after neoadjuvant therapy. pathological response will be compared primarily between these two groups. this is a randomized controlled, open-label and sequential designed clinical trial. all neoadjuvant therapy used in this study or for ptc drug screening comply with nccn (national comprehensive cancer network) or csco (chinese society of clinical oncology) guidelines.

Eligibility criteria:
inclusion criteria: * diagnosed of gastrointestinal adenocarcinoma by biopsy * existence of initially resectable lesions evaluated by investigators * indications of neoadjuvant chemotherapy including: 1) locally advanced gastric cancer ct1-2n1-3m0 \& ct3-4n0-3m0; 2) locally advanced colorectal cancer ct3-4 or n+; 3)colorectal carcinoma with synchronous liver metastases: crs≤2; 4)other patients who are considered to be appropriate to receive neoadjuvant chemotherapy determined by mdt * never receive any tumor related treatment including chemotherapy, radiotherapy, and immune therapy * never diagnosed of other malignancies * able to tolerate chemotherapy * ecog≤2 * life expectance \>6 months * at least 1 measurable lesions(according to recist 1.1) * informed consent exclusion criteria: * pregnant or lactating women * participating in other clinical trials within 6 months * msi-h or dmmr or eber(+) * lesion located within 10cm from anal margin * severe liver dysfunction * severe renal dysfunction * cognitive disorder, mental disease or poor compliance * allergic to known chemotherapeutic agents * other conditions not suitable to participate in this trial determined by investigators

Keywords: neoadjuvant chemotherapy
ultrafine endoscope for colonoscopy in diagnosis of colorectal diseases

Conditions: Colon Disease;; Rectal Disease

Summary: this study is the evaluation of ultrafine endoscope (with small caliber and turning radius )for colonoscopy in decreasing abdominal pain of patients . 60 patients will be accepted in this trial.

the aim of this study is to investigate the advantages of an endoscope with smaller turning radius and softer insert section in reducing patients' abdominal pain in colonoscopy. transnasal gastroscope was selected in this study , because of its small caliber (5.9mm) and small turning radius . visual analogue scale(vas),cecum intubation time and cecum intubation rate were evaluated.

Eligibility criteria:
inclusion criteria: 1. patients diagnostic colonoscopy; 2. subjects able to provide informed consent exclusion criteria: 1. patients with poor bowel preparation; 2. contraindications of the colonoscopy; 3. prior partial or complete colectomy
effectiveness of neurodinamic techniques on radial nerve for the treatment of lateral epicondylalgia

Conditions: Lateral Epicondylitis \(Tennis Elbow\)

Summary: lateral elbow pain is a prevalent musculoskeletal disorder in the working population due to overuse of the upper limb. this pathology has serious consequences for health, work performance and overall health burden. in this injury, as in any musculoskeletal disorder, the peripheral nervous system is involved. because of its course and corresponding motor and sensory innervation in the area, the radial nerve should be taken into consideration as a structure involved in elbow pain. the aim of the present study is to demonstrate which of the neurodynamic techniques is more effective in lateral epicondylalgia, neural tension techniques or neural mobilization techniques.

the aim of the present study is to demonstrate which is more effective among the neurodynamic techniques for lateral epicondylalgia, neural tension techniques or neural mobilization techniques. a total of 60 subjects will be recruited and divided into 2 groups. 30 in group 1 where they will receive a neural mobilization technique on the radial nerve and 30 in group 2 where they will be subjected to a neural tension technique on the radial nerve. the data to be collected will be grip strength, pain on pressure, pain and quality of life dash questionnaire, these data will be measured pre, post treatment and a re-evaluation at 4 weeks and 24 weeks after the intervention. the duration of the treatment is 6 weeks, performing two sessions per week with 72 hours of rest between sessions. a total of 12 sessions will be carried out.

Eligibility criteria:
inclusion criteria: * patient diagnosed with lateral epicondylalgia. * experiencing elbow pain of 2 to 6 months duration. * age between 30 and 60 years old. * radial humeral joint tenderness to palpation. * positive cozen\&#39;s test exclusion criteria: * - bilateral symptoms. * rheumatologic disease involving the elbow and wrist * musculoskeletal disorder due to connective tissue pathology * cervical radiculopathy * nerve compression including the upper extremity * operation on the affected arm * having received treatment for epicondylalgia in the last 6 months * radiating pain from the cervical spine * instability of the external ligamentous complex of the elbow(3). * not having received any physiotherapy session in the month prior to the start of the study. * neural clinical manifestations (electric shock-like pain, tingling, tingling, numbness and/or burning).

Keywords: epicondylalgia neural mobilization neural tension physiotherapy radial nerve
development and validation of an actimetric protocol to quantify physical activity and sedentary behaviour in post-stroke subjects

Conditions: Stroke; Chronic Stroke Patients; Stroke With Hemiparesis

Summary: the aim of this project is to develop an actimetry protocol based on a system of motion sensors, such as accelerometers and pressure insoles. these sensors will be used to analyze arm and leg movements in individuals who have experienced a stroke. throughout the study, we will adjust certain parameters-such as sensor placement and measurement frequency-to optimize data quality. we will also refine data analysis methods to better identify the types of movements performed (upper and lower limbs), estimate energy expenditure, and recognize different postures adopted by the participant (sitting, standing, etc.). the goal of this protocol is to provide accurate measurements of physical activity and inactivity, both in controlled environments (such as a laboratory) and in real-life settings (outdoors or at home). this study will allow us to validate the reliability of the actimetry protocol and assess how easy it is to use at home.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * stroke diagnosed by a neurologist and confirmed by medical imaging * more than 14 days post-stroke * medically stable condition * hemiparesis with impaired locomotion: functional ambulation classification (fac) between 1 and 5 * montreal cognitive assessment (moca) score \> 18/30 exclusion criteria: * inability to understand simple instructions * other neurological or musculoskeletal disorders limiting functional mobility

Keywords: physical activity monitoring stroke rehabilitation actimetry accelerometers pressure insoles energy expenditure estimation inactivity tracking actimetry to measure physical activity and sedentary behavior in stroke patients
transvaginal ultrasound training for obstetrics and gynecology residents

Conditions: Ovarian Cysts

Summary: obstetrics and gynecology residents are deemed to be proficient in transvaginal ultrasound (tvus) upon graduation from an accredited program, although tvus education in residency is not standardized. the objective of this study is to assess for improvement in transvaginal ultrasound knowledge among residents after viewing an educational dvd.

this is a multi-site prospective parallel randomized controlled trial using an educational dvd from the american institute of ultrasound in medicine, "gynecology: beginners only"®, compared to routine education. all participants completed a pretest on transvaginal ultrasound images and principles. the intervention group repeated the test after viewing the dvd. during the trial, performing and logging transvaginal ultrasounds were encouraged. all enrolled residents repeated the test at 6-10 months after intervention.

Eligibility criteria:
inclusion criteria: * resident in obstetrics and gynecology at one of three sites exclusion criteria: * unable to consent
nalirifox combined with pd-1 sequential radiotherapy versus ag combined with pd-1 sequential radiotherapy as first-line treatment of locally advanced pancreatic cancer

Conditions: Locally Advanced Pancreatic Cancer

Summary: the purpose of the study is to evaluate the efficacy and safety of nalirinox combined with pd-1 synchronous sequential sbrt or ag combined with pd-1 synchronous sequential sbrt as first line systematical therapy in patients with ocally advanced pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed pancreatic cancer; 2. ecog performance no more than 2; 3. radiographically assessed as locally advanced pancreatic cancer according to nccn guidelines; 4. no previous anti-tumor therapy； 5. able and willing to provide a written informed consent; exclusion criteria: * 1. prior anti-tumor therapy of any kind; 2. severe infection (\>nci ctc grade 2); 3.patients with autoimmune disease or immune deficiency who are treated with immunosuppressive drugs; 4.patients with bleeding tendency; 5. pregnant or lactating women.